Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Focal Positivity for Non-Specific Esterase in AML: A Surrogate Marker to Predict AML with t(8;21)/ RUNX1-RUNX1T1

Stefani Parmentier, MD, Nicole Birninger, Uta Oelschlägel, Brigitte Mohr, Markus Schaich, MD, Frank Kroschinsky, MD, Christian Thiede, MD, Gerhard Ehninger, MD

Blood (2011) 118 (21): 2534.

https://doi.org/10.1182/blood.V118.21.2534.2534

Published: 2011

Journal Articles

Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial

Uwe Platzbecker, Martin Wermke, Jörgen Radke, Alexander Kiani, Franzi Seltmann, Christoph Röllig, Malte von Bonin, Brigitte Mohr, Uta Oelschlägel, Johannes Schetelig, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede

Blood (2010) 116 (21): 679.

https://doi.org/10.1182/blood.V116.21.679.679

Published: 2010

Journal Articles

Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial

Friedrich Stölzel, MD, Christoph Röllig, Michael Kramer, Brigitte Mohr, Uta Oelschlägel, Jörgen Radke, Christian Thiede, Martin Bornhaeuser, MD, Gerhard Ehninger, MD, Markus Schaich, MD

Blood (2010) 116 (21): 2154.

https://doi.org/10.1182/blood.V116.21.2154.2154

Published: 2010

Journal Articles

Risk Stratification Using a New Prognostic Model for Patients with Secondary Acute Myeloid Leukemia - Results of the DSIL-AML96 Trial.

Friedrich Stölzel, Walter E. Aulitzky, Heinrich Bodenstein, Martin Bornhäuser, Michael Kramer, Brigitte Mohr, Uta Oelschlägel, Norbert Schmitz, Silke Soucek, Christian Thiede, Gerhard Ehninger, Markus Schaich

Blood (2009) 114 (22): 2652.

https://doi.org/10.1182/blood.V114.22.2652.2652

Published: 2009

Journal Articles

Dissecting the Hierarchical Level of Hematopoietic Progenitors' Involvement in AML with NPM1 Gene Mutation and Their Engraftment Potential in Immunocompromised Mice.

Blood (2009) 114 (22): 480.

https://doi.org/10.1182/blood.V114.22.480.480

Published: 2009

Journal Articles

5–azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+ Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation.

Uwe Platzbecker, Joergen Radke, Alexander Kiani, Malte Bonin, Eray Goekkurt, Uta Oelschlägel, Brigitte Mohr, Gerhard Ehninger, MD, Martin Bornhauser, MD, Christian Thiede

Blood (2008) 112 (11): 2143.

https://doi.org/10.1182/blood.V112.11.2143.2143

Published: 2008

Journal Articles

The Campath-Level at the Day of Transplant Predicts T-Cell Engraftment after Allogeneic Stem Cell Transplantation.

Johannes Schetelig, MD, Christian Thiede, PhD, Martin Bornhaeuser, PhD, Brigitte Mohr, MD, Uta Oelschlägel, MD, Gabi Geissler, MD, Rainer Schwerdtfeger, PhD, Herrad Baurmann, MD, Alexander Kiani, PhD, Uwe Platzbecker, MD, Wolfgang Siegert, PhD, Gerhard Ehninger, PhD

Blood (2006) 108 (11): 2951.

https://doi.org/10.1182/blood.V108.11.2951.2951

Published: 2006

Journal Articles

Loss of Heterozygosity Identified in Acute Myeloid Leukemia with Normal Karyotype Using SNP Microarrays.

Christine Steudel, PhD, Sofia Traikov, Uta Oelschlägel, PhD, Markus Schaich, MD, Gerhard Ehninger, MD, Christian Thiede, MD

Blood (2005) 106 (11): 760.

https://doi.org/10.1182/blood.V106.11.760.760

Published: 2005

Journal Articles

Correction of complete interferon-γ receptor 1 deficiency by bone marrow transplantation

Ursula Reuter, Joachim Roesler, Christian Thiede, Ansgar Schulz, Carl Friedrich Classen, Uta Oelschlägel, Klaus-Michael Debatin, Wilhelm Friedrich

Blood (2002) 100 (12): 4234–4235.

https://doi.org/10.1182/blood-2002-02-0433

Published: 2002

NARROW

Focal Positivity for Non-Specific Esterase in AML: A Surrogate Marker to Predict AML with t(8;21)/ RUNX1-RUNX1T1

Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial

Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial

Risk Stratification Using a New Prognostic Model for Patients with Secondary Acute Myeloid Leukemia - Results of the DSIL-AML96 Trial.

Dissecting the Hierarchical Level of Hematopoietic Progenitors' Involvement in AML with NPM1 Gene Mutation and Their Engraftment Potential in Immunocompromised Mice.

5–azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+ Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation.

The Campath-Level at the Day of Transplant Predicts T-Cell Engraftment after Allogeneic Stem Cell Transplantation.

Loss of Heterozygosity Identified in Acute Myeloid Leukemia with Normal Karyotype Using SNP Microarrays.

Correction of complete interferon-γ receptor 1 deficiency by bone marrow transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only